Results 1 to 10 of about 12,566,431 (163)

Successful immunosuppressive drug‐free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report [PDF]

Clinical Case Reports
Key Clinical Message Recommendations advise factor IX desensitization before immune tolerance induction in severe hemophilia B, supported by immunosuppression.
Ángeles Palomo Bravo, Rosario Prieto Bonilla, Daniel Bardan Rebollar, Francisco José López‐Jaime, Ihosvany Fernández‐Bello   +4 more
doaj   +2 more sources

The Clinical Genetics of Hemophilia B (Factor IX Deficiency) [PDF]

The Application of Clinical Genetics, 2021
Connie H Miller1,2 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA; 2Synergy America, Inc., Duluth, GA, USACorrespondence: Connie H MillerDivision
Miller CH
doaj   +2 more sources

A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B [PDF]

Journal of Blood Medicine
Zoran Igrutinović,1,2 Hélène Louise Hooimeijer,3 Karim Kentouche,4 Jaco Botha,5 Peter L Turecek,6 Marta Kokot-Kierepa,5 Hanna T Gazda7 1Clinic of Pediatrics, Department of Hemato-Oncology, University Clinical Center of Kragujevac, Kragujevac ...
Igrutinović Z, Hooimeijer HL, Kentouche K, Botha J, Turecek PL, Kokot-Kierepa M, Gazda HT   +6 more
doaj   +2 more sources

Encapsulation of factor IX–engineered mesenchymal stem cells in fibrinogen–alginate microcapsules enhances their viability and transgene secretion

Journal of Tissue Engineering, 2012
Cell microencapsulation holds significant promise as a strategy for cellular therapies; however, inadequate survival and functionality of the enclosed cells limit its application in hemophilia treatment.
Bahareh Sayyar, Megan Dodd, Jianping Wen, Shirley Ma, Leah Marquez-Curtis, Anna Janowska-Wieczorek, Gonzalo Hortelano   +6 more
doaj   +2 more sources

CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs [PDF]

Haematologica, 2020
Hemophilia B is an X-linked recessive bleeding disorder caused by abnormalities in the coagulation factor IX gene. Without prophylactic treatment, patients experience frequent spontaneous bleeding episodes.
Jiahuan Chen, Beiying An, Biao Yu, Xiaohuan Peng, Hongming Yuan, Qiangbing Yang, Xue Chen, Tingting Yu, Lingyu Wang, Xinwei Zhang, He Wang, Xiaodong Zou, Daxin Pang, Hongsheng Ouyang, Xiaochun Tang   +14 more
doaj   +2 more sources

Peri-operative Management and the Role of Minimally Invasive Spine Surgery in a Case of Hemophilia B [PDF]

Journal of Minimally Invasive Spine Surgery and Technique, 2022
Hemophilia A and B are rare X-chromosome-linked recessive bleeding disorders caused by mutations in the genes causing abnormalities of blood clotting factors VIII and IX, respectively.
VNR Praveen Goparaju, Amit Chugh, Ameya Rangnekar, Vishal Kundnani   +3 more
doaj   +1 more source

Haemophilia specialist nurses’ perceptions of haemophilia B

The Journal of Haemophilia Practice, 2021
Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes.
Chaplin Steve, Birkedal Maj Friberg, Crilly Erica, Fletcher Simon, Garcia Sara, Mulders Greta, Myrin-Westesson Linda, Pollard Debra, Sanigorska Anna, Uitslager Nanda   +9 more
doaj   +1 more source

The use of rIX-FP in patients with haemophilia B: a nurse's perspective

The Journal of Haemophilia Practice, 2021
The management of patients with haemophilia is complex and requires lifelong care to be delivered by a specialist multidisciplinary team. Haemophilia B results from a deficiency or absence in coagulation factor IX (FIX), leading to easy bruising, and ...
Garner Kara, Guelcher Christine, Pollard Debra   +2 more
doaj   +1 more source

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)

TH Open, 2022
In resource-rich countries, almost all severe hemophilia patients receive prophylactic replacement therapy with factor concentrates to prevent spontaneous bleeding in joints and muscles to decrease the development of arthropathy and risk of long-term ...
Tine M.H.J. Goedhart, Laura H. Bukkems, Michiel Coppens, Karin J. Fijnvandraat, Saskia E.M. Schols, Roger E.G. Schutgens, Jeroen Eikenboom, Floor C.J.I. Heubel-Moenen, Paula F. Ypma, L. Nieuwenhuizen, K. Meijer, Frank W. G. Leebeek, Ron A.A. Mathôt, Marjon H. Cnossen   +13 more
doaj   +1 more source

Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience

The Journal of Haemophilia Practice, 2021
Current treatment for severe haemophilia includes prophylactic factor replacement to prevent bleeding. Coagulation factor products have significant inter-patient variability in pharmacokinetic (PK) parameters.
Kwan Celia, Bhatt Mihir D., Strike Karen, Decker Kay, Matino Davide, Chan Anthony K.C.   +5 more
doaj   +1 more source